Bullish option flow detected in Biogen (BIIB) with 2,540 calls trading, 1.1x expected, and implied vol increasing over 2 points to 35.32%.

Shares of Biogen Inc. BIIB shed 1.16% to $141.43 Wednesday, on what proved to be an all-around great trading session for the ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...

Adjacencies and DTx The final focus area at Biogen Digital Health is digital therapeutics and other pharma-adjacent interventions. Hadjiat draws a distinction between patient-facing apps and DTx.

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...